<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36853389</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>18</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1459</ISSN><JournalIssue CitedMedium="Internet"><Volume>270</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Journal of neurology</Title><ISOAbbreviation>J Neurol</ISOAbbreviation></Journal><ArticleTitle>Association of blood lipids with onset and prognosis of amyotrophic lateral sclerosis: results from the ALS Swabia registry.</ArticleTitle><Pagination><StartPage>3082</StartPage><EndPage>3090</EndPage><MedlinePgn>3082-3090</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00415-023-11630-4</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">To date, the role of blood lipid levels and their association with the onset and prognosis of ALS is controversial. We explored these associations in a large, population-based case-control study.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Between October 2010 and June 2014, 336 ALS patients (mean age 65.7&#x2009;&#xb1;&#x2009;10.7; 57.7% male) and 487 sex- and age-matched controls from the same geographic region were recruited within the ALS registry in Southwest Germany. Triglycerides and cholesterol (high-density lipoprotein (HDL), low-density lipoprotein (LDL), total) were measured. The ALS cohort was followed up for vital status. Conditional logistic regression models were applied to calculate odds ratio (OR) for risk of ALS associated with serum lipid concentrations. In ALS patients only, survival models were used to appraise the prognostic value.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">High concentration of total cholesterol (OR 1.60, 95% confidence interval (CI) 1.03-2.49, top vs. bottom quartile), but not HDL, LDL, LDL-HDL ratio, or triglycerides, was positively associated with the risk of ALS. During the median follow-up time of 88.9&#xa0;months, 291 deaths occurred among 336 ALS patients. In the adjusted survival analysis, higher HDL (HR 1.72, 95% CI 1.19-2.50) and LDL cholesterol levels (HR 1.58, 95% CI 1.11-2.26) were associated with higher mortality in ALS patients. In contrast, higher triglyceride levels were associated with lower mortality (HR 0.68, 95% CI 0.48-0.96).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The results highlight the importance to distinguish cholesterol from triglycerides when considering the prognostic role of lipid metabolism in ALS. It further strengthens the rationale for a triglyceride-rich diet, while the negative impact of cholesterol must be further explored.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Michels</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Ulm University Hospital, University of Ulm, Oberer Eselsberg 45, 89081, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Kurz</LastName><ForeName>Deborah</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institute of Epidemiology and Medical Biometry, University of Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosenbohm</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Ulm University Hospital, University of Ulm, Oberer Eselsberg 45, 89081, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peter</LastName><ForeName>Raphael S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Institute of Epidemiology and Medical Biometry, University of Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Just</LastName><ForeName>Steffen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Molecular Cardiology, Department of Internal Medicine II, University of Ulm, 89081, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>B&#xe4;zner</LastName><ForeName>Hansj&#xf6;rg</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Katharinenhospital Stuttgart, Stuttgart, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>B&#xf6;rtlein</LastName><ForeName>Axel</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Katharinenhospital Stuttgart, Stuttgart, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dettmers</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Kliniken Schmieder Konstanz, Konstanz, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gold</LastName><ForeName>Hans-J&#xfc;rgen</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Klinikum am Gesundbrunnen Heilbronn, Heilbronn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kohler</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Klinikum am Gesundbrunnen Heilbronn, Heilbronn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naumann</LastName><ForeName>Markus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Clinic Augsburg, Augsburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ratzka</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Clinic Augsburg, Augsburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ludolph</LastName><ForeName>Albert C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Ulm University Hospital, University of Ulm, Oberer Eselsberg 45, 89081, Ulm, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center of Neurodegenerative Diseases (DZNE), Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rothenbacher</LastName><ForeName>Dietrich</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institute of Epidemiology and Medical Biometry, University of Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Nagel</LastName><ForeName>Gabriele</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Institute of Epidemiology and Medical Biometry, University of Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Dorst</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Ulm University Hospital, University of Ulm, Oberer Eselsberg 45, 89081, Ulm, Germany. johannes.dorst@uni-ulm.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center of Neurodegenerative Diseases (DZNE), Ulm, Germany. johannes.dorst@uni-ulm.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>ALS Registry Swabia Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>577 631</GrantID><Agency>German Research Council (DFG)</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>J Neurol</MedlineTA><NlmUniqueID>0423161</NlmUniqueID><ISSNLinking>0340-5354</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008055">Lipids</NameOfSubstance></Chemical><Chemical><RegistryNumber>97C5T2UQ7J</RegistryNumber><NameOfSubstance UI="D002784">Cholesterol</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014280">Triglycerides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008075">Lipoproteins, HDL</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008076">Cholesterol, HDL</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008055" MajorTopicYN="N">Lipids</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002784" MajorTopicYN="N">Cholesterol</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014280" MajorTopicYN="N">Triglycerides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008075" MajorTopicYN="N">Lipoproteins, HDL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008076" MajorTopicYN="N">Cholesterol, HDL</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Cholesterol</Keyword><Keyword MajorTopicYN="N">Hypermetabolism</Keyword><Keyword MajorTopicYN="N">Triglycerides</Keyword></KeywordList><CoiStatement>SM reported grants from the Medical Faculty of Ulm University, Germany, outside of this study. JD received funding from Nutricia GmbH, Frankfurt a.M., Germany, outside of this study.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>2</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>18</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>28</Day><Hour>11</Hour><Minute>20</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36853389</ArticleId><ArticleId IdType="pmc">PMC10193299</ArticleId><ArticleId IdType="doi">10.1007/s00415-023-11630-4</ArticleId><ArticleId IdType="pii">10.1007/s00415-023-11630-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dupuis L, Pradat PF, Ludolph AC, Loeffler JP. Energy metabolism in amyotrophic lateral sclerosis. Lancet Neurol. 2011;10:75&#x2013;82. doi: 10.1016/S1474-4422(10)70224-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70224-6</ArticleId><ArticleId IdType="pubmed">21035400</ArticleId></ArticleIdList></Reference><Reference><Citation>Peter RS, Rosenbohm A, Dupuis L, Brehme T, Kassubek J, Rothenbacher D, et al. Life course body mass index and risk and prognosis of amyotrophic lateral sclerosis: results from the ALS registry Swabia. Eur J Epidemiol. 2017;32(10):901&#x2013;908. doi: 10.1007/s10654-017-0318-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10654-017-0318-z</ArticleId><ArticleId IdType="pubmed">28975435</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakken O, Meyer HE, Stigum H, Holm&#xf8;y T. High BMI is associated with low ALS risk: a population-based study. Neurology. 2019;93(5):e424&#x2013;e432. doi: 10.1212/WNL.0000000000007861.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000007861</ArticleId><ArticleId IdType="pubmed">31243073</ArticleId></ArticleIdList></Reference><Reference><Citation>Janse Van Mantgem MR, Van Eijk RPA, Van Der Burgh HK, Tan HHG, Westeneng HJ, Van Es MA, et al. Prognostic value of weight loss in patients with amyotrophic lateral sclerosis: a population-based study. J Neurol Neurosurg Psychiatry. 2020;91(8):867&#x2013;875. doi: 10.1136/jnnp-2020-322909.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2020-322909</ArticleId><ArticleId IdType="pubmed">32576612</ArticleId></ArticleIdList></Reference><Reference><Citation>Jean CD, Preux PM, Truong CT, Courat L, Vallat JM, Couratier P. Nutritional assessment and survival in ALS patients. Amyotrophic Lateral Sclerosis. 2000;1:91&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">11467055</ArticleId></ArticleIdList></Reference><Reference><Citation>Desport JC, Preux PM, Truong TC, Vallat JM, Sautereau D, Couratier P. Nutritional status is a prognostic factor for survival in ALS patients. Neurology. 1999;53(5):1059&#x2013;1059. doi: 10.1212/WNL.53.5.1059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.53.5.1059</ArticleId><ArticleId IdType="pubmed">10496266</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasarskis EJ, Berryman S, Vanderleest JG, Schneider AR, McClain CJ. Nutritional status of patients with amyotrophic lateral sclerosis: Relation to the proximity of death. Am J Clin Nutr. 1996;63(1):130&#x2013;137. doi: 10.1093/ajcn/63.1.130.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ajcn/63.1.130</ArticleId><ArticleId IdType="pubmed">8604660</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph AC, Dorst J, Dreyhaupt J, Weishaupt JH, Kassubek J, Weiland U, et al. Effect of high-caloric nutrition on survival in amyotrophic lateral sclerosis. Ann Neurol. 2020;87(2):206&#x2013;216. doi: 10.1002/ana.25661.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25661</ArticleId><ArticleId IdType="pubmed">31849093</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorst J, Schuster J, Dreyhaupt J, Witzel S, Weishaupt JH, Kassubek J, et al. Effect of high-caloric nutrition on serum neurofilament light chain levels in amyotrophic lateral sclerosis. J Neurol, Neurosurg Psychiatry. 2020;91:1007&#x2013;1009. doi: 10.1136/jnnp-2020-323372.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2020-323372</ArticleId><ArticleId IdType="pubmed">32788256</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L, Oudart H, Ren&#xe9; F, Gonzalez De Aguilar JL, Loeffler JP. Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: benefit of a high-energy diet in a transgenic mouse model. Proc Natl Acad Sci USA. 2004;101(30):11159&#x2013;11164. doi: 10.1073/pnas.0402026101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0402026101</ArticleId><ArticleId IdType="pmc">PMC503756</ArticleId><ArticleId IdType="pubmed">15263088</ArticleId></ArticleIdList></Reference><Reference><Citation>Wills AM, Hubbard J, Macklin EA, Glass J, Tandan R, Simpson EP, et al. Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet. 2014;383(9934):2065&#x2013;2072. doi: 10.1016/S0140-6736(14)60222-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(14)60222-1</ArticleId><ArticleId IdType="pmc">PMC4176708</ArticleId><ArticleId IdType="pubmed">24582471</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouteloup C, Desport JC, Clavelou P, Guy N, Derumeaux-Burel H, Ferrier A, et al. Hypermetabolism in ALS patients: an early and persistent phenomenon. J Neurol. 2009;256(8):1236&#x2013;1242. doi: 10.1007/s00415-009-5100-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-009-5100-z</ArticleId><ArticleId IdType="pubmed">19306035</ArticleId></ArticleIdList></Reference><Reference><Citation>Funalot B, Desport JC, Sturtz F, Camu W, Couratier P. High metabolic level in patients with familial amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2009;10(2):113&#x2013;117. doi: 10.1080/17482960802295192.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960802295192</ArticleId><ArticleId IdType="pubmed">18792852</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorges M, Vercruysse P, M&#xfc;ller HP, Huppertz HJ, Rosenbohm A, Nagel G, et al. Hypothalamic atrophy is related to body mass index and age at onset in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2017;88(12):1033&#x2013;1041. doi: 10.1136/jnnp-2017-315795.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-315795</ArticleId><ArticleId IdType="pubmed">28596251</ArticleId></ArticleIdList></Reference><Reference><Citation>Vercruysse P, Sinniger J, El Oussini H, Scekic-Zahirovic J, Dieterl&#xe9; S, Dengler R, et al. Alterations in the hypothalamic melanocortin pathway in amyotrophic lateral sclerosis. Brain. 2016;139(4):1106&#x2013;1122. doi: 10.1093/brain/aww004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww004</ArticleId><ArticleId IdType="pubmed">26984187</ArticleId></ArticleIdList></Reference><Reference><Citation>Hor JH, Santosa MM, Lim VJW, Ho BX, Taylor A, Khong ZJ, et al. ALS motor neurons exhibit hallmark metabolic defects that are rescued by SIRT3 activation. Cell Death Differ. 2021;28(4):1379&#x2013;1397. doi: 10.1038/s41418-020-00664-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41418-020-00664-0</ArticleId><ArticleId IdType="pmc">PMC8027637</ArticleId><ArticleId IdType="pubmed">33184465</ArticleId></ArticleIdList></Reference><Reference><Citation>Vielhaber S, Kunz D, Winkler K, Wiedemann FR, Kirches E, Feistner H, et al. Mitochondrial DNA abnormalities in skeletal muscle of patients with sporadic amyotrophic lateral sclerosis. Brain. 2000;123(7):1339&#x2013;1348. doi: 10.1093/brain/123.7.1339.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/123.7.1339</ArticleId><ArticleId IdType="pubmed">10869047</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorst J, K&#xfc;hnlein P, Hendrich C, Kassubek J, Sperfeld AD, Ludolph AC. Patients with elevated triglyceride and cholesterol serum levels have a prolonged survival in amyotrophic lateral sclerosis. J Neurol. 2011;258(4):613&#x2013;617. doi: 10.1007/s00415-010-5805-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-010-5805-z</ArticleId><ArticleId IdType="pubmed">21128082</ArticleId></ArticleIdList></Reference><Reference><Citation>Barros ANAB, Dourado MET, Pedrosa LDFC, Leite-Lais L. Association of copper status with lipid profile and functional status in patients with amyotrophic lateral sclerosis. J Nutr Metab. 2018;2018:1&#x2013;7. doi: 10.1155/2018/5678698.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/5678698</ArticleId><ArticleId IdType="pmc">PMC6079445</ArticleId><ArticleId IdType="pubmed">30116640</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L, Corcia P, Fergani A, Gonzalez De Aguilar JL, Bonnefont-Rousselot D, Bittar R, et al. Dyslipidemia is a protective factor in amyotrophic lateral sclerosis symbol. Neurology. 2008;70(13):1004&#x2013;1009. doi: 10.1212/01.wnl.0000285080.70324.27.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000285080.70324.27</ArticleId><ArticleId IdType="pubmed">18199832</ArticleId></ArticleIdList></Reference><Reference><Citation>Che&#x142;stowska B, Bara&#x144;czyk-Ku&#x17a;ma A, Ku&#x17a;ma-Kozakiewicz M. Dyslipidemia in patients with amyotrophic lateral sclerosis&#x2013;a case control retrospective study. Amyotroph Lateral Scler Front Degener. 2021;22(3&#x2013;4):195&#x2013;205. doi: 10.1080/21678421.2020.1832119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2020.1832119</ArticleId><ArticleId IdType="pubmed">33103950</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutedja NA, Van Der Schouw YT, Fischer K, Sizoo EM, Huisman MHB, Veldink JH, et al. Beneficial vascular risk profile is associated with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2011;82(6):638&#x2013;42. doi: 10.1136/jnnp.2010.236752.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2010.236752</ArticleId><ArticleId IdType="pubmed">21471184</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xf6;rner S, Kollewe K, Ilsemann J, M&#xfc;ller-Heine A, Dengler R, Krampfl K, et al. Prevalence and prognostic impact of comorbidities in amyotrophic lateral sclerosis. Eur J Neurol. 2013;20(4):647&#x2013;654. doi: 10.1111/ene.12015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.12015</ArticleId><ArticleId IdType="pubmed">23094606</ArticleId></ArticleIdList></Reference><Reference><Citation>Cutler RG, Pedersen WA, Camandola S, Rothstein JD, Mattson MP. Evidence that accumulation of ceramides and cholesterol esters mediates oxidative stress&#x2014;induced death of motor neurons in amyotrophic lateral sclerosis. Ann Neurol. 2002;52(4):448&#x2013;457. doi: 10.1002/ana.10312.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.10312</ArticleId><ArticleId IdType="pubmed">12325074</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodge JC, Yu J, Sardi SP, Shihabuddin LS. Sterol auto-oxidation adversely affects human motor neuron viability and is a neuropathological feature of amyotrophic lateral sclerosis. Sci Rep. 2021;11(1):1&#x2013;11. doi: 10.1038/s41598-020-80378-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-80378-y</ArticleId><ArticleId IdType="pmc">PMC7804278</ArticleId><ArticleId IdType="pubmed">33436868</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng P, Zhou X. Causal effects of blood lipids on amyotrophic lateral sclerosis: A Mendelian randomization study. Hum Mol Genet. 2019;28(4):688&#x2013;697. doi: 10.1093/hmg/ddy384.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddy384</ArticleId><ArticleId IdType="pmc">PMC6360326</ArticleId><ArticleId IdType="pubmed">30445611</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartmann H, Ho WY, Chang JC, Ling SC. Cholesterol dyshomeostasis in amyotrophic lateral sclerosis: cause, consequence, or epiphenomenon? FEBS J. 2021;289:7688&#x2013;7709. doi: 10.1111/febs.16175.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/febs.16175</ArticleId><ArticleId IdType="pubmed">34469619</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagel G, &#xdc;nal H, Rosenbohm A, Ludolph AC, Rothenbacher D, Arnold G, et al. Implementation of a population-based epidemiological rare disease registry: study protocol of the amyotrophic lateral sclerosis (ALS)&#x2014;registry Swabia. BMC Neurol. 2013;13:1&#x2013;10. doi: 10.1186/1471-2377-13-22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2377-13-22</ArticleId><ArticleId IdType="pmc">PMC3582473</ArticleId><ArticleId IdType="pubmed">23414001</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2000;1(5):293&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyrer F, Bhaskaran K, Rutherford MJ. Immortal time bias for life-long conditions in retrospective observational studies using electronic health records. BMC Med Res Methodol. 2022;22(1):1&#x2013;11. doi: 10.1186/s12874-022-01581-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12874-022-01581-1</ArticleId><ArticleId IdType="pmc">PMC8962148</ArticleId><ArticleId IdType="pubmed">35350993</ArticleId></ArticleIdList></Reference><Reference><Citation>Betensky RA, Mandel M. Recognizing the problem of delayed entry in time-to-event studies: Better late than never for clinical neuroscientists. Ann Neurol. 2015;78(6):839&#x2013;844. doi: 10.1002/ana.24538.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24538</ArticleId><ArticleId IdType="pmc">PMC5502209</ArticleId><ArticleId IdType="pubmed">26452746</ArticleId></ArticleIdList></Reference><Reference><Citation>Levitan I, Singh DK, Rosenhouse-Dantsker A. Cholesterol binding to ion channels. Front Physiol. 2014;5:65. doi: 10.3389/fphys.2014.00065.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2014.00065</ArticleId><ArticleId IdType="pmc">PMC3935357</ArticleId><ArticleId IdType="pubmed">24616704</ArticleId></ArticleIdList></Reference><Reference><Citation>Korinek M, Gonzalez-Gonzalez IM, Smejkalova T, Hajdukovic D, Skrenkova K, Krusek J, et al. Cholesterol modulates presynaptic and postsynaptic properties of excitatory synaptic transmission. Sci Rep. 2020;10(1):1&#x2013;18. doi: 10.1038/s41598-020-69454-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-69454-5</ArticleId><ArticleId IdType="pmc">PMC7387334</ArticleId><ArticleId IdType="pubmed">32724221</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho WY, Chang JC, Lim K, Cazenave-Gassiot A, Nguyen AT, Foo JC, et al. Tdp-43 mediates srebf2-regulated gene expression required for oligodendrocyte myelination. J Cell Biol. 2021;220(9):e201910213. doi: 10.1083/jcb.201910213.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.201910213</ArticleId><ArticleId IdType="pmc">PMC8348376</ArticleId><ArticleId IdType="pubmed">34347016</ArticleId></ArticleIdList></Reference><Reference><Citation>Mouzat K, Molinari N, Kantar J, Polge A, Corcia P, Couratier P, et al. Liver X receptor genes variants modulate ALS phenotype. Mol Neurobiol. 2018;55(3):1959&#x2013;1965. doi: 10.1007/s12035-017-0453-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-017-0453-2</ArticleId><ArticleId IdType="pubmed">28244008</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai L, Zou L, Meng L, Qiang G, Yan M, Zhang Z. Cholesterol metabolism in neurodegenerative diseases: molecular mechanisms and therapeutic targets. Mol Neurobiol. 2021;58:2183&#x2013;2201. doi: 10.1007/s12035-020-02232-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-020-02232-6</ArticleId><ArticleId IdType="pubmed">33411241</ArticleId></ArticleIdList></Reference><Reference><Citation>Dedeene L, Van Schoor E, Ospitalieri S, Ronisz A, Weishaupt JH, Otto M, et al. Dipeptide repeat protein and TDP-43 pathology along the hypothalamic&#x2013;pituitary axis in C9orf72 and non-C9orf72 ALS and FTLD-TDP cases. Acta Neuropathol. 2020;140(5):777&#x2013;781. doi: 10.1007/s00401-020-02216-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-020-02216-9</ArticleId><ArticleId IdType="pubmed">32862270</ArticleId></ArticleIdList></Reference><Reference><Citation>Cykowski MD, Takei H, Schulz PE, Appel SH, Powell SZ. TDP-43 pathology in the basal forebrain and hypothalamus of patients with amyotrophic lateral sclerosis. Acta Neuropathol Commun. 2014;2(1):1&#x2013;11. doi: 10.1186/s40478-014-0171-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-014-0171-1</ArticleId><ArticleId IdType="pmc">PMC4297460</ArticleId><ArticleId IdType="pubmed">25539830</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilic E, Bilic E, Rudan I, Kusec V, Zurak N, Delimar D, et al. Comparison of the growth hormone, IGF-1 and insulin in cerebrospinal fluid and serum between patients with motor neuron disease and healthy controls. Eur J Neurol. 2006;13(12):1340&#x2013;1345. doi: 10.1111/j.1468-1331.2006.01503.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2006.01503.x</ArticleId><ArticleId IdType="pubmed">17116217</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacc&#xe0; F, Quarantelli M, Rinaldi C, Tucci T, Piro R, Perrotta G, et al. A randomized controlled clinical trial of growth hormone in amyotrophic lateral sclerosis: clinical, neuroimaging, and hormonal results. J Neurol. 2012;259(1):132&#x2013;138. doi: 10.1007/s00415-011-6146-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-011-6146-2</ArticleId><ArticleId IdType="pubmed">21706151</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudling M, Parini P, Angelin B. Effects of growth hormone on hepatic cholesterol metabolism. Lessons from studies in rats and humans. Growth Hormone IGF Res. 1999;9:1&#x2013;7. doi: 10.1016/S1096-6374(99)80002-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1096-6374(99)80002-1</ArticleId><ArticleId IdType="pubmed">10429873</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandres-Ciga S, Noyce AJ, Hemani G, Nicolas A, Calvo A, Mora G, et al. Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis. Ann Neurol. 2019;85(4):470&#x2013;481. doi: 10.1002/ana.25431.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25431</ArticleId><ArticleId IdType="pmc">PMC6450729</ArticleId><ArticleId IdType="pubmed">30723964</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Rheenen W, Van Der Spek RAA, Bakker MK, Van Vugt JJFA, Hop PJ, Zwamborn RAJ, et al. Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. medRxiv. 2021;53:1636&#x2013;1648.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8648564</ArticleId><ArticleId IdType="pubmed">34873335</ArticleId></ArticleIdList></Reference><Reference><Citation>McCombe PA, Henderson RD. Effects of gender in amyotrophic lateral sclerosis. Gender Med. 2010;7:557&#x2013;570. doi: 10.1016/j.genm.2010.11.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.genm.2010.11.010</ArticleId><ArticleId IdType="pubmed">21195356</ArticleId></ArticleIdList></Reference><Reference><Citation>Heiman-Patterson TD, Deitch JS, Blankenhorn EP, Erwin KL, Perreault MJ, Alexander BK, et al. Background and gender effects on survival in the TgN(SOD1-G93A)1Gur mouse model of ALS. J Neurol Sci. 2005;236(1&#x2013;2):1&#x2013;7. doi: 10.1016/j.jns.2005.02.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2005.02.006</ArticleId><ArticleId IdType="pubmed">16024047</ArticleId></ArticleIdList></Reference><Reference><Citation>Pape JA, Grose JH. The effects of diet and sex in amyotrophic lateral sclerosis. Revue Neurologique. 2020;176:301&#x2013;315. doi: 10.1016/j.neurol.2019.09.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurol.2019.09.008</ArticleId><ArticleId IdType="pmc">PMC8915943</ArticleId><ArticleId IdType="pubmed">32147204</ArticleId></ArticleIdList></Reference><Reference><Citation>Wuolikainen A, Acimovic J, L&#xf6;Vgren-Sandblom A, Parini P, Andersen PM. Bj&#xf6;Rkhem I. Cholesterol, oxysterol, triglyceride, and coenzyme q homeostasis in als. Evidence against the hypothesis that elevated 27-hydroxycholesterol is a pathogenic factor. PLoS One. 2014;9(11):e113619. doi: 10.1371/journal.pone.0113619.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0113619</ArticleId><ArticleId IdType="pmc">PMC4240598</ArticleId><ArticleId IdType="pubmed">25415378</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, Deng J, Jaffa M, Cudkowicz ME, Wills AM. Body mass index, not dyslipidemia, is an independent predictor of survival in amyotrophic lateral sclerosis. Muscle Nerve. 2011;44(1):20&#x2013;24. doi: 10.1002/mus.22114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.22114</ArticleId><ArticleId IdType="pmc">PMC4441750</ArticleId><ArticleId IdType="pubmed">21607987</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Mora G, Calvo A, Mazzini L, Bottacchi E, Mutani R. Epidemiology of ALS in Italy: a 10-year prospective population-based study. Neurology. 2009;72(8):725&#x2013;731. doi: 10.1212/01.wnl.0000343008.26874.d1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000343008.26874.d1</ArticleId><ArticleId IdType="pubmed">19237701</ArticleId></ArticleIdList></Reference><Reference><Citation>Janse van Mantgem MR, van Rheenen W, Hackeng AV, van Es MA, Veldink JH, van den Berg LH, et al. Association between serum lipids and survival in patients with amyotrophic lateral sclerosis: a meta-analysis and population-based study. Neurology. 2022 doi: 10.1212/WNL.0000000000201657.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000201657</ArticleId><ArticleId IdType="pmc">PMC9990853</ArticleId><ArticleId IdType="pubmed">36460467</ArticleId></ArticleIdList></Reference><Reference><Citation>Pikhart H, Hub&#xe1;&#x10d;ek JA, Peasey A, Kub&#xed;nov&#xe1; R, Bob&#xe1;k M. Association between fasting plasma triglycerides, all-cause and cardiovascular mortality in Czech population. Results from the HAPIEE study. Physiol Res. 2015;64:S355&#x2013;S361. doi: 10.33549/physiolres.933179.</Citation><ArticleIdList><ArticleId IdType="doi">10.33549/physiolres.933179</ArticleId><ArticleId IdType="pubmed">26680668</ArticleId></ArticleIdList></Reference><Reference><Citation>Owen OE, Morgan AP, Kemp HG, Sullivan JM, Herrera MG, Cahill GF. Brain metabolism during fasting. J Clin Invest. 1967;46(10):1589&#x2013;1595. doi: 10.1172/JCI105650.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI105650</ArticleId><ArticleId IdType="pmc">PMC292907</ArticleId><ArticleId IdType="pubmed">6061736</ArticleId></ArticleIdList></Reference><Reference><Citation>Steyn FJ, Li R, Kirk SE, Tefera TW, Xie TY, Tracey TJ, et al. Altered skeletal muscle glucose-fatty acid flux in amyotrophic lateral sclerosis. Brain Commun. 2020;2:fcaa154. doi: 10.1093/braincomms/fcaa154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcaa154</ArticleId><ArticleId IdType="pmc">PMC7677608</ArticleId><ArticleId IdType="pubmed">33241210</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorst J, Doenz J, Kandler K, Dreyhaupt J, Tumani H, Witzel S, et al. Fat-rich versus carbohydrate-rich nutrition in ALS: a randomised controlled study. J Neurol Neurosurg Psychiatry. 2022;93(3):298&#x2013;302. doi: 10.1136/jnnp-2021-328331.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2021-328331</ArticleId><ArticleId IdType="pubmed">35022317</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>